ARENA PHARMACEUTICALS INC's ticker is ARNA and the CUSIP is 040047607. A total of 216 filers reported holding ARENA PHARMACEUTICALS INC in Q2 2019. The put-call ratio across all filers is 0.93 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $643,000 | +37.4% | 6,927 | +2.6% | 0.00% | 0.0% |
| Q1 2021 | $468,000 | +70.2% | 6,749 | +88.4% | 0.00% | – |
| Q4 2020 | $275,000 | +100.7% | 3,583 | +95.6% | 0.00% | – |
| Q3 2020 | $137,000 | -17.0% | 1,832 | -30.3% | 0.00% | – |
| Q2 2020 | $165,000 | +432.3% | 2,628 | +284.8% | 0.00% | – |
| Q4 2019 | $31,000 | -91.1% | 683 | -91.0% | 0.00% | -100.0% |
| Q3 2019 | $348,000 | +866.7% | 7,624 | +1115.9% | 0.00% | – |
| Q2 2019 | $36,000 | -82.4% | 627 | -88.1% | 0.00% | -100.0% |
| Q4 2018 | $205,000 | +11.4% | 5,281 | +32.0% | 0.00% | 0.0% |
| Q3 2018 | $184,000 | -53.4% | 4,000 | -55.9% | 0.00% | -50.0% |
| Q2 2018 | $395,000 | -57.8% | 9,074 | -61.7% | 0.00% | -95.1% |
| Q1 2018 | $935,000 | +79.8% | 23,682 | +54.6% | 0.04% | +86.4% |
| Q4 2017 | $520,000 | +27.5% | 15,317 | -4.3% | 0.02% | +29.4% |
| Q3 2017 | $408,000 | +2814.3% | 16,005 | +1712.6% | 0.02% | +1600.0% |
| Q2 2017 | $14,000 | – | 883 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 252,500 | $11,320,000 | 4.95% |
| Rubric Capital Management LP | 857,103 | $38,424,000 | 3.59% |
| PFM Health Sciences, LP | 3,255,230 | $145,932,000 | 3.22% |
| Partner Investment Management, L.P. | 40,605 | $1,820,000 | 2.10% |
| DAFNA Capital Management LLC | 93,942 | $4,211,000 | 1.82% |
| Atika Capital Management LLC | 195,000 | $8,742,000 | 1.78% |
| Perceptive Advisors | 1,400,171 | $62,770,000 | 1.77% |
| EMORY UNIVERSITY | 47,779 | $2,142,000 | 1.51% |
| Rhenman & Partners Asset Management AB | 234,558 | $10,515,000 | 1.23% |
| Eversept Partners, LP | 75,721 | $3,394,572 | 0.99% |